Finding a role for zalcitabine in the HAART era

Antiviral Therapy

Volumn 3, Issue 3, 1998, Pages 125-137

  Moyle, Graeme J ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; LAMIVUDINE; NUCLEOSIDE ANALOG; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

DRUG ACTIVITY; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; MOUTH ULCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION;

ANTI-HIV AGENTS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; LAMIVUDINE; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

EID: 0031740357     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Follansbee S, Drew L, Olsen R et al. The efficacy of zalcitabine (ddC, HIVID) versus zidovudine (ZDV) as monotherapy in ZDV naive patients with advanced HIV disease: a randomized, double-blind comparative trial (ACTG 114; N3300). IXth International Conference on AIDS, Berlin, June 1993; Abstract PO-B26-2113.
2. Abrams DI, Goldman AI, Launer C, Korvick JA, Neaton JD, Crane LR, Grodesky M, Wakefield S, Muth K & Kornegay S. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. New England Journal of Medicine 1994; 330:657-662.
3. Fischl MA, Stanley K, Collier AC, Arduino JM, Stein DS, Feinberg JE, Allan JD, Goldsmith JC & Powderly WG. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Annals of Internal Medicine 1995; 122:24-32.
4. BHIVA Guidelines Coordinating Committee. British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349:1086-1092.
5. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG & Volberding PA. Antiretroviral therapy for HIV infection in 1998. Journal of the American Medical Association 1998; 280:78-86.
6. Stellbrink HJ, van Lunzen J, Hufert FT, Froschle G, Wolf-Vorbeck G, Zollner B, Albrecht H, Greten H, Racz P & Tenner-Racz K. Asymptomatic HIV infection is characterized by rapid turnover of HIV RNA in plasma and lymph nodes but not of latently infected lymph-node CD4+ T cells. AIDS 1997; 11:1103-1110.
7. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, Sun E, Henry D, Rode R, Potthoff A & Leonard J. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998; 351:543-549.
8. Moyle GJ. Viral resistance patterns selected by antirerroviral drugs and their potential to guide treatment choice. Expert Opinion on Investigational Drugs 1997; 6:943-964.
9. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA & Fischl MA. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New England Journal of Medicine 1997; 337:725-733.
10. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348:283-291.
11. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS & Merigan TC. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. New England Journal of Medicine 1996; 335:1081-1090.
12. Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pettinelli C, Stein DS, Markowitz N, Reves R, Loveless MO, Crane L, Thompson M ̈ Abrams D. Zidovudine alone or in combination with zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. New England Journal of Medicine 1996; 335:1099-1106.
13. CAESAR coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349:1413-1421.
14. Haubrich R, Lalezari J, Follansbee SE, Gill MJ, Hirsch M, Richman D, Mildvan D, Burger HU, Beattie D, Donatacci L, Salgo MP and the NV14256 study team. Improved survival and reduced clinical progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine. Antiviral Therapy 1998; 3:33-42.
15. Chen MS & Oshana SC. Inhibition of HIV reverse transcriptase by 2',3'-dideoxycytidine triphosphate. Biochemical Pharmacology 1987; 36:4361-4362.
16. Plageman PGW, Wohlhueter RM & Woffendin C. Nucleoside and nucleobase transport in animal cells. Biochimica et Biophysica Acta 1988; 947:405-443.
17. Broder S. Pharmacodynamics of 2',3'-dideoxycytidine:an inhibitor of human immunodeficiency virus. American Journal of Medicine 1990; 88 (Suppl. 5B):S3-S7.